Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GSK to launch late-stage testing of syncytial virus vaccine

10/21/2020 | 12:58am EST
A GSK logo is seen on a flag at a GSK research centre in Stevenage

FRANKFURT (Reuters) - GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results.

RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years.

The area is a key growth opportunity for GSK, as it seeks to offset declining sales of its blockbuster lung drug Advair due to generic competition.

GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.

A separate product, designed to give pregnant women the ability to confer immunity to their unborn children, led to high levels of protective neutralising antibodies in non-pregnant healthy woman taking part in a Phase I/II trial.

GSK said Phase III studies, with the potential to produce data for regulatory approval, would likely start over the coming months.

The vaccines were well-tolerated with side effects including injection-site pain and headache, GSK added.

Companies including Johnson &, Sanofi and Moderna are competing to get a vaccine approved against RSV, which globally leads to about 3 million hospital stays for children under five per year.

Swedish Orphan Biovitrum's Synagis, a monthly shot, is currently the only preventive treatment against RSV in high-risk infants. Sanofi and partner AstraZeneca are working on longer-acting nirsevimab, which could be given once per cold season to that group, if approved.

GSK is also conducting early-stage studies of an RSV vaccine for children and plans to publish results some time between Oct. 26-29 for a subgroup of children which already had some exposure to the virus.

(Reporting by Ludwig Burger. Editing by Jane Merriman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
GLAXOSMITHKLINE PLC 0.83% 1390 Delayed Quote.-21.87%
MODERNA, INC. 10.78% 109.18 Delayed Quote.458.18%
SANOFI 1.37% 85.37 Real-time Quote.-4.74%
SWEDISH ORPHAN BIOVITRUM AB 4.42% 154.9 Delayed Quote.-3.98%
All news about GLAXOSMITHKLINE PLC
06:12aFrench health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24AstraZeneca Gears Up to Vaccinate the World Against Covid-19
DJ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
AQ
11/23GLAXOSMITHKLINE : GSK starts phase 3 study of RSV maternal candidate vaccine
PU
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
11/20VECTURA : provides update on GSK litigation
AQ
11/19VECTURA : U.S. Appeals Court Upholds Ruling Against GlaxoSmithKline
DJ
11/19GLAXOSMITHKLINE : GSK and MMV present positive data on treatment for Plasmodium ..
PU
More news
Financials
Sales 2020 34 219 M 45 626 M 45 626 M
Net income 2020 4 855 M 6 474 M 6 474 M
Net Debt 2020 22 921 M 30 562 M 30 562 M
P/E ratio 2020 14,0x
Yield 2020 5,80%
Capitalization 68 623 M 91 855 M 91 500 M
EV / Sales 2020 2,68x
EV / Sales 2021 2,53x
Nbr of Employees 99 437
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 712,02 GBX
Last Close Price 1 378,60 GBX
Spread / Highest target 70,5%
Spread / Average Target 24,2%
Spread / Lowest Target -19,8%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-22.51%91 855
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555